Alterity Therapeutics Announced Presentation Of New Data Demonstrating Potential Of ATH434 To Treat Rare Neurodegenerative Disease Friedreich's Ataxia
Alterity Therapeutics Announced Presentation Of New Data Demonstrating Potential Of ATH434 To Treat Rare Neurodegenerative Disease Friedreich's Ataxia
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that important new data on its lead drug candidate ATH434 was presented at the World Orphan Drug Congress USA 2024 in Boston, MA. The poster, entitled, "Biophysical Characteristics of ATH434, a Unique Iron-Targeting Drug for Treating Friedreich's Ataxia", was presented by Ashley Pall, Department of Pharmaceutical Sciences at Wayne State University. The study evaluated the ability of ATH434 to target the toxic form of iron that drives the pathology of Friedreich's Ataxia, a rare neurodegenerative disease that affects young children to young adults. The study also evaluated traditional iron chelators that are designed to bind iron and remove iron from the body. Conversely, an iron chaperone is designed to bind and redistribute iron within the bod
致力於開發神經退行性疾病改良療法的生物技術公司Alterity Therapeutics（（澳大利亞證券交易所股票代碼：ATH，納斯達克股票代碼：ATH）（“Alterity” 或 “公司”）今天宣佈，其主要候選藥物 ATH434 的重要新數據已在馬薩諸塞州波士頓舉行的2024年美國世界孤兒藥大會上公佈。這張海報名爲 “用於治療弗裏德賴希共濟失調的獨特鐵靶向藥物 ATH434 的生物物理特性”，由韋恩州立大學藥物科學系的阿什利·帕爾主持。該研究評估了 ATH434 靶嚮導致弗裏德賴希共濟失調病理的有毒鐵的能力，弗裏德賴希共濟失調是一種罕見的神經退行性疾病，會影響幼兒到年輕人。該研究還評估了旨在結合鐵和去除體內鐵的傳統鐵螯合劑。相反，鐵監護人旨在綁定和重新分配體內鐵質
譯文內容由第三人軟體翻譯。